Antinuclear and antinative DNA antibodies during captopril treatment.
Antinuclear antibodies (ANA) developed in 13 out of 78 patients treated with captopril for a mean period of 11 months. In another 11 patients, who were ANA-positive before captopril therapy, no increase in ANA titer was observed during treatment. Neither the development nor the presence of ANA before captopril treatment were associated with (drug-induced) lupus erythematosus or increased incidence of clinical side-effects, although development of ANA was accompanied by a serum-sickness-like syndrome in one patient. The ANA were mainly of the IgM class, did not fix complement and were transiently present. In three patients, antinative DNA antibodies, exclusively of IgM class and not complement-fixing, were transiently present without clinical signs of systemic lupus erythematosus, although recurrence of these antibodies was associated with slight proteinuria in one of them.
D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis / Q000276:immunology*; D002216:Captopril / Q000009:adverse effects / Q000276:immunology*; D004247:DNA / Q000276:immunology*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007075:Immunoglobulin M / Q000032:analysis; D008297:Male; D008875:Middle Aged; D011392:Proline / Q000031:analogs & derivatives*; D011446:Prospective Studies
D000974:Antibodies, Antinuclear; D007075:Immunoglobulin M; D004247:DNA; D011392:Proline; D002216:Captopril